SPRO
Income statement / Annual
Last year (2023), Spero Therapeutics, Inc.'s total revenue was $96.74 M,
an increase of 99.13% from the previous year.
In 2023, Spero Therapeutics, Inc.'s net income was $22.81 M.
See Spero Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$96.74 M
|
$48.58 M
|
$18.26 M
|
$9.33 M
|
$4.74 M
|
$3.97 M
|
$1.98 M
|
$335,000.00
|
$0.00
|
| Cost of Revenue |
$367,000.00 |
$1.55 M |
$1.12 M |
$67.00 M |
$65.78 M |
$33.89 M |
$32.87 M |
$26.33 M |
$11,000.00 |
| Gross Profit |
$96.37 M |
$47.03 M |
$17.14 M |
-$57.67 M |
-$61.03 M |
-$29.92 M |
-$30.89 M |
-$26.00 M |
-$11,000.00 |
| Gross Profit Ratio |
1 |
0.97 |
0.94 |
-6.18 |
-12.87 |
-7.54 |
-15.61 |
-77.61 |
0 |
| Research and Development
Expenses |
$51.07 M
|
$47.59 M
|
$64.53 M
|
$67.00 M
|
$65.78 M
|
$33.89 M
|
$32.87 M
|
$26.33 M
|
$11.13 M
|
| General & Administrative
Expenses |
$25.55 M
|
$36.48 M
|
$41.70 M
|
$21.44 M
|
$15.59 M
|
$12.89 M
|
$10.84 M
|
$7.22 M
|
$2.20 M
|
| Selling & Marketing
Expenses |
$566,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$25.55 M
|
$36.48 M
|
$41.70 M
|
$21.44 M
|
$15.59 M
|
$12.89 M
|
$10.84 M
|
$7.22 M
|
$2.20 M
|
| Other Expenses |
-$14,000.00 |
-$4.93 M |
-$395,000.00 |
$833,000.00 |
-$13.41 M |
$1.14 M |
-$4.37 M |
$0.00 |
$174,000.00 |
| Operating Expenses |
$76.63 M |
$79.15 M |
$106.23 M |
$88.44 M |
$67.96 M |
$42.81 M |
$41.73 M |
$33.56 M |
$13.33 M |
| Cost And Expenses |
$76.99 M |
$79.15 M |
$106.23 M |
$88.44 M |
$67.96 M |
$42.81 M |
$41.73 M |
$33.56 M |
$13.33 M |
| Interest Income |
$3.94 M |
$1.11 M |
$346,000.00 |
$401,000.00 |
$1.33 M |
$1.14 M |
$303,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$2.61 M |
$1.94 M |
$0.00 |
$0.00 |
$303,000.00 |
$303,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$367,000.00
|
$1.55 M
|
$1.12 M
|
$1.35 M
|
$1.16 M
|
$409,000.00
|
$363,000.00
|
$279,000.00
|
$11,000.00
|
| EBITDA |
$20.11 M
|
-$18.94 M
|
-$87.37 M
|
-$79.11 M
|
-$63.22 M
|
-$42.81 M
|
-$41.73 M
|
-$33.52 M
|
-$13.49 M
|
| EBITDA Ratio |
0.21 |
-0.39 |
-4.79 |
-8.48 |
-13.33 |
-10.79 |
-21.09 |
-100.07 |
0 |
| Operating Income Ratio
|
0.2
|
-0.87
|
-4.82
|
-8.48
|
-13.33
|
-10.79
|
-21.09
|
-99.17
|
0
|
| Total Other
Income/Expenses Net |
$5.66 M
|
-$4.22 M
|
-$1.79 M
|
$833,000.00
|
$2.29 M
|
$1.14 M
|
-$4.37 M
|
$580,000.00
|
$174,000.00
|
| Income Before Tax |
$25.40 M |
-$46.42 M |
-$89.76 M |
-$78.28 M |
-$60.93 M |
-$41.66 M |
-$46.10 M |
-$32.64 M |
-$13.15 M |
| Income Before Tax Ratio
|
0.26
|
-0.96
|
-4.92
|
-8.39
|
-12.85
|
-10.5
|
-23.29
|
-97.44
|
0
|
| Income Tax Expense |
$2.60 M |
$1.61 M |
$1.55 M |
-$761,000.00 |
-$750,000.00 |
$1.14 M |
-$363,000.00 |
-$7.73 M |
-$3.17 M |
| Net Income |
$22.81 M |
-$48.03 M |
-$91.30 M |
-$77.52 M |
-$60.18 M |
-$41.66 M |
-$46.10 M |
-$25.49 M |
-$10.15 M |
| Net Income Ratio |
0.24 |
-0.99 |
-5 |
-8.31 |
-12.69 |
-10.5 |
-23.29 |
-76.09 |
0 |
| EPS |
0.43 |
-1.28 |
-2.96 |
-3.46 |
-3.31 |
-2.6 |
-17.82 |
-3.86 |
-1.54 |
| EPS Diluted |
0.43 |
-1.28 |
-2.96 |
-3.46 |
-3.31 |
-2.6 |
-17.82 |
-3.86 |
-1.54 |
| Weighted Average Shares
Out |
$52.70 M
|
$37.59 M
|
$30.90 M
|
$22.39 M
|
$18.16 M
|
$16.00 M
|
$2.59 M
|
$6.60 M
|
$6.60 M
|
| Weighted Average Shares
Out Diluted |
$52.99 M
|
$37.59 M
|
$30.90 M
|
$22.39 M
|
$18.16 M
|
$16.00 M
|
$2.59 M
|
$6.60 M
|
$6.60 M
|
| Link |
|
|
|
|
|
|
|
|
|
